Investment Management
* Xtandi Expected To Reap $1 Billion: Medivation’s prostate cancer drug, Xtandi, is expected to reap $1 biilion in revenue by 2017. However, this loot is shared with Astellas and is Medivation’s sole revenue source. While Medivation only had $190 million from the total $518 million obtained from Xtandi’s sales in 3Q, analysts see $1.9 […]
* The American College of Cardiology’s annual meeting reports that Edwards Lifesciences Corp.’s newest aortic valve, Sapien 3, which is implanted through a catheter and allows patients to avoid open heart surgery, has a lower risk of death or stroke than surgery in intermediate-risk people who currently can’t get the device * The findings presented at […]
* Enterprise Products Partners, largest publicly traded midstream MLP, is one of the best proxies to profit from the eventual uptrend in oil prices. Trading at 18 times earnings and paying an attractive yield of 6.30 percent, EPD is going to climb to $30.00 by end 2016 and should be bought on any weakness * […]
* We concur with Barron’s and see Endo Pharmaceuticals, a specialty drug maker rising at least 50 percent over the next two years wit the introduction of generic versions of its cholesterol medicine Zetia and bipolar treatment Seroquel XR. Shares of the company are down 53% this year amid an industry rout fueled by concern […]
* Flash Storage: EMC, IBM & HPE Lead The Pack: A Stifel Nicolaus report that partly relies on figures supplied by Gartner indicates the all-flash storage array (“AFA”) market grew 91% Y/Y in Q4 to $1.05B. 102% growth was recorded in Q3 * Gartner’s numbers indicate EMC’s (NYSE:EMC) XtremIO unit is still easily the biggest […]
Sign up our newsletter for FREE financial advice and investment tips delivered to your inbox on weekly basis.
Want to keep in touch with news from Blue Phoenix Financials? Subscribe to our RSS feed using by clicking on the button to the right, or subscribe to our newsletter by filling out the form below.